Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
521-540 of 1,307 trials

Ovarian Cancer: Sacituzumab Tirumotecan Study

We are testing a new treatment for people with recurrent ovarian cancer to see if it works better than standard care. This study looks at safety, tolerability, and how it affects patients' quality of life.

Recurrent Ovarian CancerConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementOncology

Endometrial Cancer: New Treatment Combinations

We are studying whether a new combination of Trastuzumab Deruxtecan with Rilvegostomig or Pembrolizumab is more effective than standard chemotherapy for patients with advanced or recurrent HER2-expressing endometrial cancer.

Endometrial CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Biliary Tract Cancer: T-DXd and Rilvegostomig Study

We are studying a new treatment combination for patients with advanced HER2-expressing biliary tract cancer. The goal is to see if it helps improve survival compared to standard care options.

Advanced HER2-expressing Biliary Tract Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Castrate-Resistant Prostate Cancer: Acetylsalicylic Acid and Atorvastatin Study

We are investigating whether acetylsalicylic acid and atorvastatin can improve survival in patients with castrate-resistant prostate cancer. The study will also look at other health impacts and safety of these medications.

Castration-Resistant Prostate CancerConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyUrology

Advanced Colon Cancer: Preoperative Chemotherapy Study

We are investigating whether chemotherapy before surgery is more effective than surgery followed by additional treatment for advanced colon cancer. This trial aims to improve treatment strategies for patients.

Colon Cancer (Stage T3-4)>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Polymyalgia Rheumatica: Secukinumab Safety Study

We are evaluating the long-term safety of secukinumab for individuals with polymyalgia rheumatica. This study will help us understand any potential side effects associated with this treatment.

Polymyalgia Rheumatica>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Breast Cancer Treatment for Women 70+: Radiation vs. Hormone Therapy

We are comparing radiation therapy and hormone therapy for older women with early-stage luminal A-like breast cancer. The goal is to see which treatment better controls cancer and improves quality of life.

Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Childhood Absence Epilepsy: Brivaracetam Safety Study

We are studying the long-term safety of brivaracetam in children and young adults with childhood or juvenile absence epilepsy. This research aims to understand how well the medication is tolerated over time.

Childhood Absence EpilepsyJuvenile Absence Epilepsy>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

Atopic Dermatitis: Amlitelimab Treatment Study

We are studying two dosing schedules of amlitelimab for people aged 12 and older with moderate-to-severe atopic dermatitis. The goal is to see if it helps maintain treatment response compared to stopping treatment.

Atopic Dermatitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Advanced Biliary Cancer: Personalized Targeted Therapy

We are studying whether a new personalized treatment can help patients with advanced biliary cancer live longer without disease progression compared to standard care. This trial also examines the quality of life and safety of the new therapies.

Advanced Biliary Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineOncology

Lymphoblastic Lymphoma: New Treatment Protocol for Kids

We are studying whether changing medications during treatment can help reduce relapses in the brain for children and adolescents with lymphoblastic lymphoma. This trial aims to improve survival rates and treatment outcomes compared to standard approaches.

Lymphoblastic Lymphoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

COVID-19 Treatment: Anti-Coronavirus Immunoglobulin Study

We are testing a new immunoglobulin treatment for adults recently diagnosed with COVID-19 to see if it improves health outcomes compared to a placebo. This study aims to understand its safety and effectiveness alongside standard care.

COVID-19≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Anakinra for Persistent Respiratory Symptoms After COVID-19

We are studying whether anakinra can help patients with ongoing respiratory issues after COVID-19 improve their symptoms and immune function. This trial is for those experiencing long-term effects of the virus.

Post-Acute COVID Syndrome≤3 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesInfectious DiseasesInternal MedicinePulmonology

Long-Term Follow-Up of CAR T-Cell Therapy Patients

We are studying the long-term effects and safety of CAR T-cell therapy in patients who have received this treatment. This includes monitoring for delayed side effects and the persistence of modified T-cells in the blood.

Multiple MyelomaB-cell LymphomaB-cell Type Acute Leukaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Heart Procedure: Short vs. Long Antiplatelet Therapy

We are studying whether a shorter duration of antiplatelet therapy after a heart procedure is as safe and effective as the standard longer treatment. This trial is for patients who have had coronary angioplasty for blocked arteries.

Chronically Occluded Coronary Artery>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Dexamethasone for Severe Hospital-Acquired Pneumonia

We are studying whether dexamethasone can improve outcomes for critically ill patients with severe hospital-acquired pneumonia. This trial will also assess safety and how patients feel about the treatment.

Hospital-acquired Pneumonia>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Uveal Melanoma: New Liver Treatment with Ipilimumab and Nivolumab

We are testing a new liver treatment combined with two immunotherapy drugs for patients with uveal melanoma that has spread to the liver. This study aims to see if the new approach improves survival without disease progression compared to standard treatment.

Uveal Melanoma with Liver Metastases3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesHepatologyOncology

Heart Failure: Balcinrenone/Dapagliflozin Study

We are evaluating a new treatment combining balcinrenone and dapagliflozin for patients with heart failure and kidney problems. The study aims to see if this combination reduces heart-related events and improves health compared to standard treatment.

Chronic Heart Failure1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCardiologyNephrology

Fragile X Syndrome: Long-Term Study of ZYN002 Gel

We are examining the long-term safety and tolerability of a gel medication for children and young adults with Fragile X Syndrome. This study includes participants who have previously used the medication and are continuing to see if it helps manage their symptoms.

Fragile X Syndrome≤3 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurologyPediatrics

Meningococcal Vaccine Study for Infants and Toddlers

We are investigating a new meningococcal vaccine to see how well it works and its safety compared to an existing vaccine in healthy infants and toddlers. This study focuses on children receiving their first doses at 6-7 months and a booster at 12-13 months.

Meningococcal Infection6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPediatrics